SARS-CoV-2 and COVID-19

2021 ◽  
Author(s):  
Rosalind Hollingsworth
Keyword(s):  
Distress Syndrome ◽  
Multiorgan Failure ◽  
Mainland China ◽  
Respiratory Illness ◽  
Infected Person ◽  
Increased Risk ◽  
Asymptomatic Infections ◽  
Novel Coronavirus ◽  
Inflammatory Syndrome ◽  
Respiratory Droplets

Coronavirus disease 19 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus which emerged in Wuhan, China in 2019, and from there spread to other parts of mainland China and around the world. The virus spreads mainly through respiratory droplets produced when an infected person coughs, sneezes, or speaks. On average, the time from exposure to SARS-CoV-2 to the appearance of symptoms is 5–6 days but can range from 1–14 days. Asymptomatic infections with SARS-CoV-2 can occur. In those with symptoms, most people (approx. 80%) will experience a mild to moderate respiratory illness and recover without hospital management. Adults 65 years of age and older, and individuals of any age with underlying medical conditions, are at increased risk for severe COVID-19 and death. Complications include respiratory failure, acute respiratory distress syndrome, sepsis/septic shock, thromboembolism, multiorgan failure and death. In rare cases, children and adults can develop a severe inflammatory syndrome a few weeks after SARS-COV-2 infection. Vaccines are available to help prevent COVID-19 disease; by August 2021, 7 vaccines had been authorized for use by the WHO to prevent COVID-19 caused by SARS-CoV-2, with others approved by country regulatory authorities.

scholarly journals Responding to the COVID-19 pandemic in Ghana

2020 ◽  
Vol 54 (2) ◽  
pp. 72-73
Author(s):  
Ernest Kenu ◽  
Joseph Frimpong ◽  
Kwadwo Koram
Keyword(s):  
Respiratory Distress ◽  
Distress Syndrome ◽  
Rna Virus ◽  
Respiratory Illness ◽  
The United States ◽  
World Health ◽  
Infected Person ◽  
Wuhan City ◽  
Novel Coronavirus ◽  
Health Organization

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China. The disease was christened COVID-19 and the pathogen (an RNA virus) identified as SARS-Coronavirus-2 (SARS-CoV-2).1,2 The virus is primarily spread through contact with small droplets produced from coughing, sneezing, or talking by an infected person. While a substantial proportion of infected individuals may remain asymptomatic, the most common symptoms in clinical cases include, fever, cough, acute respiratory distress, fatigue, and failure to resolve over 3 to 5 days of antibiotic treatment. Complications may include pneumonia and acute respiratory distress syndrome.3 Over five million confirmed cases of COVID-19 has been recorded globally with more than 300,000 deaths as at 25th May 2020. The United States of America has recorded the highest number of cases with more than 1.5 million and over 100,000 deaths.4 In Africa, more than 90,0000 cases have been reported with about 3,000 deaths. South Africa has recorded the highest number of cases with 23,615 cases and 481 deaths. Ghana confirmed its first cases of COVID-19 on 12th March 2020 and had as at 25 May 2020 recorded over 7,000 cases with 34 deaths.5  

scholarly journals Acute Lower Limb Ischemia Secondary to COVID-19: A Case Report

2021 ◽  
Vol 11 (6) ◽  
pp. 161-163
Author(s):  
Komal Gharsangi ◽  
Rajesh Bhawani ◽  
Nitesh Kumar
Keyword(s):  
Lower Limb ◽  
Distress Syndrome ◽  
Multiorgan Failure ◽  
Clinical Manifestations ◽  
Limb Ischemia ◽  
Respiratory Illness ◽  
Acute Limb Ischemia ◽  
Poor Clinical Outcome ◽  
Rare Manifestation ◽  
Thrombotic Complications

COVID -19 is not just a respiratory illness; it is a great masquerader with clinical manifestations from pneumonia, acute respiratory distress syndrome to endothelial dysfunction, hypercoagulability and multiorgan failure. Thrombotic complications due to Covid related coagulopathy is of concern as it further leads to poor clinical outcome in severe cases of Covid 19. Acute limb ischemia (ALI) is a rare manifestation of Covid related coagulopathy. Key words: COVID, coagulopathy, acute limb ischemia (ALI).

scholarly journals COVID-19 Global Pandemic Planning: Decontamination and Reuse Processes for N95 Respirators

2020 ◽  
Author(s):  
Douglas J Perkins ◽  
Steven Villescas ◽  
Terry H. Wu ◽  
Timothy Muller ◽  
Steven Bradfute ◽  
...  
Keyword(s):  
Operating Room ◽  
Healthcare Providers ◽  
Respiratory Illness ◽  
Lessons Learned ◽  
Healthcare Personnel ◽  
Environmental Controls ◽  
Global Pandemic ◽  
Increased Risk ◽  
Novel Coronavirus ◽  
N95 Respirators

ABSTRACTCoronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified as a cluster of respiratory illness in Wuhan City, Hubei Province, China in December 2019, and has rapidly spread across the globe to greater than 200 countries. Healthcare providers are at an increased risk for contracting the disease due to occupational exposure and require appropriate personal protective equipment (PPE), including N95 respirators. The rapid worldwide spread of high numbers of COVID-19 cases has facilitated the need for a substantial supply of PPE that is largely unavailable in many settings, thereby creating critical shortages. Creative solutions for the decontamination and safe reuse of PPE to protect our frontline healthcare personnel are essential. Here, we describe the development of a process that began in late February 2020 for selecting and implementing the use of hydrogen peroxide vapor (HPV) as viable method to reprocess N95 respirators. Since pre-existing HPV decontamination chambers were not available, we optimized the sterilization process in an operating room after experiencing initial challenges in other environments. Details are provided about the prioritization and implementation of processes for collection and storage, pre-processing, HPV decontamination, and post-processing of filtering facepiece respirators (FFRs). Important lessons learned from this experience include, developing an adequate reserve of PPE for effective reprocessing and distribution, and identifying a suitable location with optimal environmental controls (i.e., operating room). Collectively, information presented here provides a framework for other institutions considering decontamination procedures for N95 respirators.

scholarly journals Multiorgan Involvement in COVID-19 and Possible Therapies

2020 ◽  
Vol 04 (01) ◽  
pp. 20-24
Author(s):  
Prachee Sathe ◽  
Vijay Sundar Singh
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
World Health Organization ◽  
Distress Syndrome ◽  
Respiratory Illness ◽  
World Health ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

AbstractIn late 2019, China reported cases of respiratory illness in humans, which involved a novel Coronavirus SARS-CoV-2 (also known as 2019-nCoV). The World Health Organization (WHO) termed the disease COVID-19 (i.e., Coronavirus disease 2019). Most of the morbidity and mortality from COVID-19 is largely due to acute viral pneumonitis that leads to acute respiratory distress syndrome (ARDS). This article will discuss the clinical features of the multiorgan involvement in COVID-19 as well as the management of patients who become critically ill due to COVID-19.

scholarly journals COVID-19 and diabetes: How to manage?

2020 ◽  
Vol 4 (1) ◽  
pp. 1-2
Author(s):  
R. Maskey ◽  
P.P. Gupta
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Adult Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Multiorgan Failure ◽  
Increased Risk ◽  
Patients With Diabetes

Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multiorgan failure. Depending on the global region, 20–50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes.

scholarly journals Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets

2020 ◽  
Vol 21 (21) ◽  
pp. 8081 ◽  
Author(s):  
Harry Karmouty-Quintana ◽  
Rajarajan A. Thandavarayan ◽  
Steven P. Keller ◽  
Sandeep Sahay ◽  
Lavannya M. Pandit ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Vascular Dysfunction ◽  
Treatment Options ◽  
Renin Angiotensin System ◽  
Respiratory Illness ◽  
1918 Influenza ◽  
Novel Coronavirus

The 1918 influenza killed approximately 50 million people in a few short years, and now, the world is facing another pandemic. In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an international outbreak of a respiratory illness termed coronavirus disease 2019 (COVID-19) and rapidly spread to cause the worst pandemic since 1918. Recent clinical reports highlight an atypical presentation of acute respiratory distress syndrome (ARDS) in COVID-19 patients characterized by severe hypoxemia, an imbalance of the renin–angiotensin system, an increase in thrombogenic processes, and a cytokine release storm. These processes not only exacerbate lung injury but can also promote pulmonary vascular remodeling and vasoconstriction, which are hallmarks of pulmonary hypertension (PH). PH is a complication of ARDS that has received little attention; thus, we hypothesize that PH in COVID-19-induced ARDS represents an important target for disease amelioration. The mechanisms that can promote PH following SARS-CoV-2 infection are described. In this review article, we outline emerging mechanisms of pulmonary vascular dysfunction and outline potential treatment options that have been clinically tested.

scholarly journals Varying Presentations of Multisystem Inflammatory Syndrome Temporarily Associated with COVID-19

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Jasmina Krikilion ◽  
Lisa Nuyttens ◽  
Siel Daelemans ◽  
Karlien François ◽  
Reiner Mauel ◽  
...  
Keyword(s):  
Distress Syndrome ◽  
Early Recognition ◽  
Clinical Manifestations ◽  
Toxic Shock ◽  
Clinical Presentations ◽  
Atypical Kawasaki Disease ◽  
Case Presentations ◽  
Novel Coronavirus ◽  
Inflammatory Syndrome ◽  
Beneficial Outcome

Background. A novel coronavirus identified in 2019 leads to a pandemic of severe acute respiratory distress syndrome with important morbidity and mortality. Initially, children seemed minimally affected, but there were reports of cases similar to (atypical) Kawasaki disease or toxic shock syndrome, and evidence emerges about a complication named paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C). Case Presentations. Two cases were compared and discussed demonstrating varying presentations, management, and evolution of MIS-C. These cases are presented to increase awareness and familiarity among paediatricians and emergency physicians with the different clinical manifestations of this syndrome. Discussion. MIS-C may occur with possible diverse clinical presentations. Early recognition and treatment are paramount for a beneficial outcome.

scholarly journals A Review on Current Situation of Coronavirus (COVID-19)

2021 ◽  
pp. 28-32
Author(s):  
Arif S. Shekh ◽  
Jayshri V. Thorat ◽  
Aijaz A. Sheikh ◽  
K. R. Biyani
Keyword(s):  
Respiratory Illness ◽  
Chronic Respiratory Disease ◽  
Medical Problem ◽  
Special Treatment ◽  
Infected Person ◽  
Virus Spread ◽  
Serious Illness ◽  
Respiratory Droplets ◽  
Corona Viruses ◽  
Primary Transmission

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problem like cardiovascular disease, Diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The best way to prevent and solve down transmission is to be well informed it causes and how it spread. Protect yourself and other from infection by washing your hands or using alcohol base rub frequently and not touching your face. The COVID-19 virus spread primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes, so it’s important that you also practice respiratory etiquette (for ex. by coughing into a flexed elbow).The COVID-19 is a respiratory illness and the primary transmission of C0VID-19 route is through person to person contact and through when a contact infected person coughs or sneezes with respiratory droplets. No evidence of viruses that causes respiratory illness being transmitted via food or packaging. Corona viruses multiply in animal or human host, they cannot multiply in food.

scholarly journals Covid-19 Pandemic-Insights and Challenges

2020 ◽  
Vol 1 (4) ◽  
pp. 070-087
Author(s):  
Lakshmi S ◽  
Shehna S ◽  
Vimal S ◽  
Midhu GV ◽  
Shiny DV ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Features ◽  
Distress Syndrome ◽  
Vaccine Development ◽  
Severe Pneumonia ◽  
Respiratory Illness ◽  
The Public ◽  
Clinical Presentations ◽  
Genetic Makeup ◽  
Novel Coronavirus

The 2019 Novel Coronavirus (2019-nCoV) outbreak affected a large number of deaths with millions of confirmed cases worldwide. Coronavirus Disease (COVID-19) is associated with respiratory illness that lead to severe pneumonia and Acute Respiratory Distress Syndrome (ARDS). Although related to the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), Covid-19 shows some unique pathogenetic, epidemiological and clinical features. On the basis of the phylogenetic relationship as well as genomic structures, the Covid-19 belongs to genera Betacoronavirus. Human Betacoronaviruses (SARS-CoV-2, SARS-CoV, and MERS-CoV) have shared similarities, yet differences also in their genomic and phenotypic level that influence the pathogenesis. To gain knowledge regarding the pathophysiology and virulence of the Covid-19 virus, it is absolutely necessary to understand its genetic makeup, transmission, virulence factors, risk factors, diagnosis, clinical presentations, outcome predictions, management of risk factors and ways to control the disease thus providing an insight to the current or future treatment and management protocols. To provide a review of the differences in pathogenesis, epidemiology and clinical features of Covid-19, its transmission and replication dynamics, genome organization, current clinical trials and vaccine development strategies, Immunoinformatics, diagnostics and ways to control the pandemic, inorder to raise an increasing awareness, both to the public and for scientific perspectives.

scholarly journals Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19

2020 ◽  
Author(s):  
Stuart P Weisberg ◽  
Thomas Connors ◽  
Yun Zhu ◽  
Matthew Baldwin ◽  
Wen-Hsuan Lin ◽  
...  
Keyword(s):  
Distress Syndrome ◽  
Severe Disease ◽  
Clinical Manifestations ◽  
Serological Response ◽  
The Novel ◽  
N Protein ◽  
Mild Disease ◽  
Patient Groups ◽  
Novel Coronavirus ◽  
Inflammatory Syndrome

Clinical manifestations of COVID-19 caused by the novel coronavirus SARS-CoV-2 are associated with age. While children are largely spared from severe respiratory disease, they can present with a SARS-CoV-2-associated multisystem inflammatory syndrome (MIS-C) similar to Kawasaki's disease. Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease. There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while both COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs. Moreover, MIS-C patients had reduced neutralizing activity compared to COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.

Sign in / Sign up

Export Citation Format

Share Document